Locations:
Search IconSearch
February 15, 2022/Cancer

Let’s Talk About Childhood Cancer Survivorship (Podcast)

Seth Rotz, MD, joins the Cancer Advances podcast to share insights

Pediatric cancer survivor

More children are surviving childhood cancers than ever before. Each year in the United States about 15,000 children are diagnosed with cancer, and about 80% to 85% will survive five years or longer.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

While these numbers are encouraging, pediatric oncologists say a shift to better longer-term management of pediatric cancer survivors is warranted. The Childhood Cancer Survivorship Program at Cleveland Clinic Children’s is focused on doing just that.

Led by pediatric hematologist/oncologist Seth Rotz, MD, the physicians work with pediatric cancer survivors, their families, and other subspecialists as needed to identify risks and monitor late effects associated with disease and its treatment. They also provide counsel and resources related to other concerns, such as family planning and psychosocial issues.

Dr. Rotz joined the Cancer Advances podcast to discuss the goals of the program, the biggest issues in childhood cancer survivorship programs, and the next exciting thing in the field.

An excerpt from the podcast

“Our focus in cancer survivorship has focused a great deal on the medical effects of having received chemotherapy and radiation. And, I think, in the last several years, there’s just been more attention focused on questions like: What are the long-term psychological impacts? What are the financial impacts of having had cancer? Does this impact whether a teenager ends up applying to college or not? Or does it put somebody in a position where they can’t change jobs because they’re worried about health insurance coverage and so forth,” he says.

“And then we have so many people and parents, too, who have some degree of post-traumatic stress from their treatment, and so we are trying to identify different mental health issues that can go along with treatment and get people plugged in with the resources they need, which is another very important part of what we do.”

Advertisement

Featured in Cleveland Clinic Children's 2022 Year in Review

Advertisement

Related Articles

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Baby's feet
April 3, 2025/Cancer/News & Insight
Fertility Preservation Counseling for Young Adults with Cancer

Growing need for addressing fertility concerns

CAR T cell
March 28, 2025/Cancer/News & Insight
What’s New and on the Horizon for Treating Multiple Myeloma?

Making sense of the fast-moving treatment landscape

Myelofibrosis cells
March 18, 2025/Cancer/News & Insight
Personalizing Treatment of Myelofibrosis-Associated Anemia

Combination therapy may help address underlying disease

Basal cell carcinoma
March 14, 2025/Cancer/News & Insight
Definitive Radiation Therapy Effective for Treating Locally Advanced Basal Cell Carcinoma

Major study demonstrates importance of having a multidisciplinary approach to treatment for large, locally advanced tumors

PET scan
March 4, 2025/Cancer/News & Insight
Case Study: First Patient at Cleveland Clinic Treated with Tumor-Infiltrating Lymphocyte Therapy

Highly personalized treatment shrinks tumors resistant to immunotherapy

Ad